Pulse Insulin Therapy Remains Noncovered

Outpatient intravenous insulin therapy (OIVIT) is to remain nationally noncovered. The Centers for Medicare & Medicaid Services (CMS) recently concluded that OIVIT does not improve health outcomes and is not reasonable and necessary for any indication.

CMS posted, Sept. 25, a decision memo in regards to a National Coverage Analysis (NCA) it initiated last March to determine whether OIVIT improves health outcomes in Medicare beneficiaries with type 2 diabetes and should be considered medically necessary and nationally covered.

OIVIT consists of an outpatient regimen of pulsatile or continuous intravenous infusion of insulin by any means, guided by the measurement results of one or more of the following:

  • respiratory quotient
  • urine urea nitrogen (UUN)
  • arterial, venous or capillary glucose
  • potassium concentration

The treatment is performed in scheduled recurring intermittent episodes.

You have until Oct. 25 to comment on this NCA (CAG-00410N). CMS expects to finalize this NCA for OIVIT by Dec. 24.

dec-clearance-sale

Latest posts by admin aapc (see all)

Leave a Reply

Your email address will not be published. Required fields are marked *